<DOC>
	<DOCNO>NCT00311662</DOCNO>
	<brief_summary>Overall trial objective : - Can treatment tonabersat reduce number day migraine headache patient suffer frequent migraine attack - How well tolerate treatment tonabersat The study base hypothesis unique mechanism action tonabersat inhibit early event generation migraine effective prophylactic treatment</brief_summary>
	<brief_title>Efficacy Tolerability Tonabersat Prophylaxis Migraine Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Migraine Aura</mesh_term>
	<criteria>An established history migraine least one year , without aura , meet diagnostic criterion International Classification Headache Disorders , experience four 14 migraine headache day per month ; headache day experience within least two six migraine attack per month . Women child bear potential must use reliable form contraception ( define protocol ) least three month prior enrolment contraception maintain least 7 day last dose study medication must negative pregnancy test screen intention become pregnant study period . Patients diagnosis migraine accord diagnostic criterion International Classification Headache Disorders age 50 year . Experience frequent nonmigraine headache Patients pure menstrual migraine define patient migraine attack occur exclusively Day 1 +/ 2 ( i.e . Days 2 +3 ) menstruation least two three menstrual cycle time cycle . Patients significant central nervous system disorder opinion investigator . Failure respond two adequately dose ( i.e . recommend total daily dose sufficient duration ) migraine prophylactic medication . Overuse acute migraine treatment define 14 medication day per month analgesic opioids nine medication day per month ergot triptans . Prophylactic treatment within two month prior entry trial . Patients take following medication : betablockers ( last two month ) , tricyclic antidepressant ( last two month ) , antiepileptic drug ( last two month ) , calcium channel blocker ( last two month ) , monoamine oxidase inhibitor ( last two month ) , daily oral NSAIDs , daily paracetamol , high dose magnesium supplement ( 600 mg/day ) , daily multivitamin preparation contain 10 mg riboflavin , daily use oral corticosteroid daily herbal preparation ( e.g . feverfew , butterwort St John 's Wort ) . Parenteral administration Botulinum toxin also exclude . Patients take medication use prophylaxis migraine include methysergide , anti spasticity agent ( e.g . tizanidine ) new generation antipsychotic ( e.g . olanzapine ) currently within previous two month also exclude . Patients , opinion investigator , significant cerebrovascular disease , e.g . transient ischaemic attack , stroke . Patients , opinion investigator , clinically significant cardiovascular disease . Patients suffer current clinical diagnosis major depressive disorder schizophrenia . Patients renal dysfunction , define serum creatinine great 125 % upper limit normal age group . Patients hepatic dysfunction define liver function test ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , alkaline phosphatase , bilirubin ) great twice upper limit normal age group . Patients know alcohol substance abuse . Failure complete diary card baseline period . Participation another clinical trial previous four week . Any woman pregnant , lactate use medically acceptable contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>